biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 2-million-dollar fee

<< Previous

Bullboard Posts

Next >>

Comment by narmacon Jan 19, 2023 9:16pm

103 Views

Post# 35234673

RE:RE:2-million-dollar fee

Hummmm,,are they paying you as well,,zwerp,,,???,,,did you read the Medammune validation data?,,..abstract and all,,,,did it tell you anything you didnt already know?,,,like even the smallest of points ,,,,,if possible, could you help the board undersatnd where xB3s worthlessness is and where exactly Medammune failed in their research. Thanks in advance.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market